Article

A common druggable signature of oncogenic CMYC, mutant KRAS and mutant p53 reveals functional redundancy and competition of the oncogenes in cancer

2023-12-21

Abstract excerpt

Major driver oncogenes CMYC , mutant KRA S and mutant TP53 often co-exist and cooperate in promoting human neoplasia. By CRISPR-Cas9-mediated downregulation we determined their proteomics and transcriptomics downstream programs in a panel of cell lines with activated either single or three oncogenes – in cancers of lung, colon and pancreas. This allowed to define and screen the oncogenes’ common functional prog...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 81bcd001-d76b-5efb-9c71-174586c94c6c
DOI: 10.1101/2023.12.20.572548

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A common druggable signature of oncogenic CMYC, mutant KRAS and mutant p53 reveals functional redundancy and competition of the oncogenes in cancerDOI 10.1101/2023.12.20.572548Read

A common druggable signature of oncogenic c-Myc, mutant KRAS and mutant p53 reveals functional redundancy and competition among oncogenes in cancer.Semantic proximity Read

A Driver Never Works Alone—Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human CancerSemantic proximity Read

A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.Semantic proximity Read

Comprehensive Analysis of Co-Mutations Identifies Cooperating Mechanisms of TumorigenesisSemantic proximity Read

Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype.Semantic proximity Read

Molecular Mechanisms of Synergistic Effect of PRIMA-1met and Oxaliplatin in Colorectal Cancer With Different p53 Status.Semantic proximity Read

SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status.Semantic proximity Read

Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations.Semantic proximity Read

How Cancer Genomics Drives Cancer Biology: Does Synthetic Lethality Explain Mutually Exclusive Oncogenic Mutations?Semantic proximity Read

The prominent pervasive oncogenic role and tissue specific permissiveness of RAS gene mutations.Semantic proximity Read

How Cancer Genomics Drives Cancer Biology: Does Synthetic Lethality Explain Mutually Exclusive Oncogenic Mutations?Semantic proximity Read

Gene signature critical to cancer phenotype as a paradigm for anticancer drug discovery.Semantic proximity Read